Alnylam Pharmaceuticals Inc. inked its third significant deal of the year, signing an exclusive alliance agreement to develop and commercialize ALN-RSV01, its lead RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection, with Japanese firm Kyowa Hakko Kogyo Co. Ltd. (BioWorld Today)